Other Information.
−Removed: Rostislav Raykov , a current member of our Board of Directors , adopted a trading arrangement on September 23, 2024 , which is intended to satisfy the Rule 10b5-1 affirmative defense.
−Removed: This trading arrangement covers the disposition of up to 120,000 shares of the Company’s common shares, and will terminate on December 31, 2025 , unless earlier terminated in accordance with its terms.
−Removed: No additional directors or officers informed us of the adoption, modification or termination of a “ Rule 10b5-1 trading arrangement” or “non- Rule 10b5-1 trading arrangement ,” as those terms are defined in Regulation S-K, Item 408.
−Removed: On November 8, 2024, we issued a press release announcing our financial results for the quarter ended September 30, 2024.
+Added: Insider Trading Arrangements and Policies
+Added: During the quarter ended March 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.
+Added: Press Release
+Added: On May 13, 2025, we issued a press release announcing our financial results for the quarter ended March 31, 2025.
A copy of the news release is attached to this Quarterly Report as Exhibit 99.1.
3 unchanged sentences
Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
−Removed: Press Release for Quarter Ended September 30, 2024 (filed herewith).
+Added: Press Release for Quarter Ended March 31, 2024 (filed herewith).
Inline XBRL Instance Document
6 unchanged sentences
information contained in Exhibits 101)
+Added: In accordance with Item 601(b)(10)(iv) of Regulation S-K, certain provisions and terms of this exhibit have been redacted.
+Added: Fennec will provide an unredacted copy of the exhibit on a supplemental basis to the SEC or its staff upon request.
Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Fennec Pharmaceuticals Inc.
−Removed: November 8, 2024
−Removed: /s/ Jeff Hackman
+Added: /s/ Jeffrey Hackman
+Added: Jeffrey Hackman
Chief Executive Officer
(principal executive officer)
−Removed: November 8, 2024
/s/ Robert Andrade
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.